“Lab at your fingertip” technology requiring no additional equipment with pending EUA application delivers 100% sensitivity and 100% specificity in BEI study
| SPRINGDALE, Ark., Dec. 7, 2020 /PRNewswire/ -- NOWDiagnostics, Inc. announced today that study results for its ADEXUSDx® COVID-19 antibody test yielded encouraging test performance—providing a strong use case for the innovative diagnostic device, which was filed for Emergency Use Authorization (EUA) from the U.S. Food and Drug Administration (FDA) on May 29, 2020. The antibody test delivered 100 percent sensitivity and 100 percent specificity in a well-characterized 45 sample panel of COVID-19 positive and negative patient samples, provided by the Biodefense and Emerging Infections Research Resources Repository (BEI Resources) panel.
In August 2020, the Biomedical Advanced Research and Development Authority (BARDA), part of the Office of the Assistant Secretary for Preparedness and Response at the U.S. Department of Health and Human Services, provided funding and technical support to NOWDiagnostics for the delivery of a high-quality serological test for SARS-CoV-2 antibodies. The test can be used across a variety of health care settings—from hospital emergency rooms to clinics—and ultimately, by consumers for at-home use. As part of this cost-sharing contract, BARDA recommended evaluation of the ADEXUSDx® COVID-19 antibody test with the BEI panel. The ADEXUSDx® COVID-19 Test is a rapid serology, self-contained assay that measures the presence of SARS-CoV-2 antibodies and delivers lab-quality results in 15 minutes with no buffers, reagents, or additional equipment. The test requires only a drop of blood (either capillary blood from a simple fingerstick or 40 μL of venous whole blood, serum, or plasma) and has the potential to be deployed directly into homes and workplaces. Reliable antibody tests will play a critical role in understanding the number of people who have been infected with COVID-19 and are potentially immune, as well as in the development and administration of COVID-19 therapies and vaccines. Availability of point-of-care (POC) and over-the-counter (OTC) tests would allow individuals to be screened easily and quickly, yielding test results in minutes instead of days. NOWDiagnostics submitted an application to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) of the test on May 29, 2020. The application is still pending. If FDA authorizes emergency use, C19 Development, LLC, a wholly owned subsidiary of NOWDiagnostics, will begin offering the ADEXUSDx® COVID-19 Test for use in CLIA-certified laboratories across a variety of health care settings—from clinics to hospital emergency rooms. Clinical trials for OTC test use are ongoing. NOWDiagnostics, Inc., based in Springdale, Arkansas, is a leader in innovative diagnostics testing. Its ADEXUSDx® product line features a lab at your fingertip, using a single drop of blood to test for a variety of common conditions, illnesses, and diseases, with results in a matter of minutes. By eliminating the need to send tests to off-site laboratories, NOWDiagnostics products have the potential to decrease the waiting period to determine test results by days. For more information about NOWDiagnostics, visit www.nowdx.com. For more information about the ADEXUSDx® COVID-19 Test, including its intended use, features, benefits and limitations, and directions for use, visit www.c19development.com. The ADEXUSDx® COVID-19 Test will be distributed by C19 Development, LLC, a wholly owned subsidiary of NOWDiagnostics. Laboratories may contact www.c19development.com/order to place an order.
SOURCE NOWDiagnostics |
View original content to download multimedia: